Keya Medical
AI for Smarter Healthcare
About
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating products that empower healthcare providers by optimizing efficiency, improving accuracy, and increasing precision.
Keya Medical has developed solutions for specialties including cardiology, radiology, neurology, pathology, and surgery. Since 2016, we have collaborated with more than 725 hospitals to improve care delivery on a global scale.
Diagnostic Solutions
Treatment Solutions
Core Products
DeepVessel FFR
DeepVessel FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
CuraRad® – ICH
R&D Pipeline
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment maintenance.
Latest News
DeepVessel 3D Visualization Processing Software Receives Regulatory Approval in China
Keya Medical has received regulatory approval in China for its DeepVessel 3D Visualization Processing Software. The AI-based software medical device is designed for visualization reading of multiphase CT images and 3D models.
Deep Learning-based CT-FFR Reduces the Need for Invasive Coronary Angiography
A new study conducted by researchers at the First Affiliated Hospital of Jinan University demonstrates that deep learning-based CT-FFR (DL-CTFFR) can reduce the need for invasive coronary angiography (ICA) and improve outcomes in patients with stable coronary artery disease (CAD).
Moving Toward a Coronary CTA-first Strategy: Current Evidence, Guidelines, & Recommendations
Evidence is building in support of a coronary CTA-first strategy for evaluating patients with stable coronary artery disease. Learn more about the current evidence, guidelines, and recommendations.
Let’s transform the future of healthcare together
